Breaking Down Kidney Disease: From Guidelines to Prognostic Profiling

News
Video

Recent Videos
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Donna H Ryan, MD Obesity Expert Highlights 2021 Research Success and Looks to 2022 and Beyond
Related Content
FDA Approves First Generic of Liraglutide Injection to Improve Glycemic Control in Patients with Type 2 Diabetes / Image credit: ©Argus/AdobeStock

FDA Approves First Generic of Liraglutide Injection to Improve Glycemic Control in Patients with Type 2 Diabetes

Sydney Jennings
December 23rd 2024
Article

The FDA has approved the first generic once-daily GLP-1 injection for the improvement of glycemic control for type 2 diabetes in patients 10 years and up.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

Sydney Jennings
June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

CagriSema Leads to Weight Reduction of Approximately 23% in Phase 3 REDEFINE 1 Clinical Trial / image credit ©JHVE photo/stock.adobe.com

CagriSema Leads to Weight Reduction of Approximately 23% in Phase 3 REDEFINE 1 Clinical Trial, Short of the 25% Expected

Grace Halsey
December 20th 2024
Article

The 22.7% weight loss at 68 weeks places CagriSema essentially on par with, not superior to, competing antiobesity drugs including Lilly's tirzepatide.

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

Sydney Jennings
July 22nd 2022
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

Antiobesity Drugs May Help Curb Alcohol Consumption: Daily Dose / image credit: ©New Africa/AdobeStock

Antiobesity Drugs May Help Curb Alcohol Consumption: Daily Dose

Sydney Jennings
December 12th 2024
Article

Your daily dose of the clinical news you may have missed.

More than Half of US Adults Eligible for Semaglutide: Daily Dose / image credit: ©New Africa/AdobeStock

More than Half of US Adults Eligible for Semaglutide: Daily Dose

Sydney Jennings
December 9th 2024
Article

Your daily dose of the clinical news you may have missed.

© 2024 MJH Life Sciences

All rights reserved.